The impact of funding cuts on medical research resonates deeply across the healthcare landscape, threatening not only the advancement of science but also the fundamental safety of patients involved in clinical trials.With significant reductions in medical research funding, particularly from sources like NIH research grants, there is a growing risk to essential oversight mechanisms, such as those provided by Institutional Review Boards (IRBs).